126 related articles for article (PubMed ID: 34787423)
1. Targeting a Novel KRAS Binding Site: Application of One-Component Stapling of Small (5-6-mer) Peptides.
Fumagalli G; Carbajo RJ; Nissink JWM; Tart J; Dou R; Thomas AP; Spring DR
J Med Chem; 2021 Dec; 64(23):17287-17303. PubMed ID: 34787423
[TBL] [Abstract][Full Text] [Related]
2. Selective apoptosis-inducing activity of synthetic hydrocarbon-stapled SOS1 helix with d-amino acids in H358 cancer cells expressing KRAS
Xu LL; Li CC; An LY; Dai Z; Chen XY; You QD; Hu C; Di B
Eur J Med Chem; 2020 Jan; 185():111844. PubMed ID: 31706640
[TBL] [Abstract][Full Text] [Related]
3. Computationally Empowered Workflow Identifies Novel Covalent Allosteric Binders for KRAS
Mortier J; Friberg A; Badock V; Moosmayer D; Schroeder J; Steigemann P; Siegel F; Gradl S; Bauser M; Hillig RC; Briem H; Eis K; Bader B; Nguyen D; Christ CD
ChemMedChem; 2020 May; 15(10):827-832. PubMed ID: 32237114
[TBL] [Abstract][Full Text] [Related]
4. Structure-based inhibitor design of mutant RAS proteins-a paradigm shift.
Nyíri K; Koppány G; Vértessy BG
Cancer Metastasis Rev; 2020 Dec; 39(4):1091-1105. PubMed ID: 32715349
[TBL] [Abstract][Full Text] [Related]
5. Small molecule binding sites on the Ras:SOS complex can be exploited for inhibition of Ras activation.
Winter JJ; Anderson M; Blades K; Brassington C; Breeze AL; Chresta C; Embrey K; Fairley G; Faulder P; Finlay MR; Kettle JG; Nowak T; Overman R; Patel SJ; Perkins P; Spadola L; Tart J; Tucker JA; Wrigley G
J Med Chem; 2015 Mar; 58(5):2265-74. PubMed ID: 25695162
[TBL] [Abstract][Full Text] [Related]
6. K-Ras
Feng H; Zhang Y; Bos PH; Chambers JM; Dupont MM; Stockwell BR
Biochemistry; 2019 May; 58(21):2542-2554. PubMed ID: 31042025
[TBL] [Abstract][Full Text] [Related]
7. Direct small-molecule inhibitors of KRAS: from structural insights to mechanism-based design.
Ostrem JM; Shokat KM
Nat Rev Drug Discov; 2016 Nov; 15(11):771-785. PubMed ID: 27469033
[TBL] [Abstract][Full Text] [Related]
8. Andrographolide derivatives inhibit guanine nucleotide exchange and abrogate oncogenic Ras function.
Hocker HJ; Cho KJ; Chen CY; Rambahal N; Sagineedu SR; Shaari K; Stanslas J; Hancock JF; Gorfe AA
Proc Natl Acad Sci U S A; 2013 Jun; 110(25):10201-6. PubMed ID: 23737504
[TBL] [Abstract][Full Text] [Related]
9. Discovery of potent SOS1 inhibitors that block RAS activation via disruption of the RAS-SOS1 interaction.
Hillig RC; Sautier B; Schroeder J; Moosmayer D; Hilpmann A; Stegmann CM; Werbeck ND; Briem H; Boemer U; Weiske J; Badock V; Mastouri J; Petersen K; Siemeister G; Kahmann JD; Wegener D; Böhnke N; Eis K; Graham K; Wortmann L; von Nussbaum F; Bader B
Proc Natl Acad Sci U S A; 2019 Feb; 116(7):2551-2560. PubMed ID: 30683722
[TBL] [Abstract][Full Text] [Related]
10. [A peptide inhibitor of the binding site of oncoproteins of the p21ras family].
Mzareulov KD
Biofizika; 2005; 50(3):413-7. PubMed ID: 15977829
[TBL] [Abstract][Full Text] [Related]
11. Development of new anti-cancer peptides from conformational energy analysis of the oncogenic ras-p21 protein and its complexes with target proteins.
Pincus MR
Front Biosci; 2004 Sep; 9():3486-509. PubMed ID: 15353372
[TBL] [Abstract][Full Text] [Related]
12. Identification of the sites of interaction between c-Raf-1 and Ras-GTP.
Barnard D; Diaz B; Hettich L; Chuang E; Zhang XF; Avruch J; Marshall M
Oncogene; 1995 Apr; 10(7):1283-90. PubMed ID: 7731678
[TBL] [Abstract][Full Text] [Related]
13. Drugging "undruggable" genes for cancer treatment: Are we making progress?
Duffy MJ; Crown J
Int J Cancer; 2021 Jan; 148(1):8-17. PubMed ID: 32638380
[TBL] [Abstract][Full Text] [Related]
14. 'Hot spot' amino acid distribution in Ha-ras oncogene product p21: relationship to guanine binding site.
Cosic I; Hearn MT
J Mol Recognit; 1991; 4(2-3):57-62. PubMed ID: 1810347
[TBL] [Abstract][Full Text] [Related]
15. Targeting KRAS mutant cancers by preventing signaling transduction in the MAPK pathway.
Korzeniecki C; Priefer R
Eur J Med Chem; 2021 Feb; 211():113006. PubMed ID: 33228976
[TBL] [Abstract][Full Text] [Related]
16. Multivalent Small-Molecule Pan-RAS Inhibitors.
Welsch ME; Kaplan A; Chambers JM; Stokes ME; Bos PH; Zask A; Zhang Y; Sanchez-Martin M; Badgley MA; Huang CS; Tran TH; Akkiraju H; Brown LM; Nandakumar R; Cremers S; Yang WS; Tong L; Olive KP; Ferrando A; Stockwell BR
Cell; 2017 Feb; 168(5):878-889.e29. PubMed ID: 28235199
[TBL] [Abstract][Full Text] [Related]
17. NMR in integrated biophysical drug discovery for RAS: past, present, and future.
Marshall CB; KleinJan F; Gebregiworgis T; Lee KY; Fang Z; Eves BJ; Liu NF; Gasmi-Seabrook GMC; Enomoto M; Ikura M
J Biomol NMR; 2020 Nov; 74(10-11):531-554. PubMed ID: 32804298
[TBL] [Abstract][Full Text] [Related]
18. Multi-target, ensemble-based virtual screening yields novel allosteric KRAS inhibitors at high success rate.
Gupta AK; Wang X; Pagba CV; Prakash P; Sarkar-Banerjee S; Putkey J; Gorfe AA
Chem Biol Drug Des; 2019 Aug; 94(2):1441-1456. PubMed ID: 30903639
[TBL] [Abstract][Full Text] [Related]
19. Isoform-Specific Destabilization of the Active Site Reveals a Molecular Mechanism of Intrinsic Activation of KRas G13D.
Johnson CW; Lin YJ; Reid D; Parker J; Pavlopoulos S; Dischinger P; Graveel C; Aguirre AJ; Steensma M; Haigis KM; Mattos C
Cell Rep; 2019 Aug; 28(6):1538-1550.e7. PubMed ID: 31390567
[TBL] [Abstract][Full Text] [Related]
20. KRAS: A Promising Therapeutic Target for Cancer Treatment.
Wu HZ; Xiao JQ; Xiao SS; Cheng Y
Curr Top Med Chem; 2019; 19(23):2081-2097. PubMed ID: 31486755
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]